Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

CRDL.TO Debt Repayment

Cash used to repay borrowings during the period.

Cardiol Therapeutics Inc.TSX: CRDL.TO

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment grows, but more slowly than its trailing trend

Q1 FY2026 debt repayment of CA$13.84K (cash outflow) rose 0.0% year over year, behind the +33.3% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Debt repayment grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +33.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$13.84K+0.0% QoQ
Last fiscal yearDec 2025
-CA$55.38K+33.3% YoY
LTMMar 2026
-CA$55.38K+33.3% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+33.3%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

CAD · from the cash flow

Latest · FY2025
(55.38K) CAD
Year-over-year change
-33.3%

Debt Repayment vs competitors

How CRDL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.3% is the highest of 2, against a peer median of -10.1%.
  • Over three fiscal years its annual growth of +0.9% compares with a peer median of +244.7%.
CRDL.TO Competitors
Debt Repayment for CRDL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$20.2M USD-10.1%+244.7%36.2%
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$55.38K CAD+33.3%+0.9%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$0 USD———
Peer median (excluding CRDL.TO) —-10.1%+244.7%36.2%

Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
Deferred Income Tax(4.92M)0(1.59M)00
Stock-Based Compensation8.5M5.01M4.17M14.28M10.7M
Change in Working Capital76.52K5.75M746.8K(931.57K)(733.34K)
Accounts Receivables(59.95K)(144.18K)67.18K(81.75K)135.43K
Inventory17.97K(4.47M)000
Accounts Payables2.39M4.47M(1.29M)(1.06M)263.69K
Other Working Capital(2.27M)5.89M679.62K214.93K(1.13M)
Other Non-Cash Items4.21M(7.27M)(627.28K)(2.1M)(105.34K)
Operating Cash Flow(23.55M)(27.22M)(25.18K)(25.06M)(23.85M)
Capital Expenditures(12.92K)(74.71K)(64)(21.29K)(24.48K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(64.25K)00
Investing Cash Flow(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Debt Repayment(51.92K)(53.93K)(55.38K)(41.53K)(55.38K)
Common Stock Issued84.08M0021.36M16.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.35M0(55.38K)(2.47M)(477.03K)
Financing Cash Flow93.44M(53.93K)(55.38K)18.84M15.54M
Effect of Forex Changes(11.13K)2.92M762.04K1.89M(824.04K)
Net Change in Cash69.87M(24.43M)(24.54M)(4.35M)(9.16M)
Free Cash Flow(23.56M)(27.3M)(25.24K)(25.08M)(23.88M)

Cardiol Therapeutics Inc.

TSX:CRDL.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.